Stock Scorecard
Stock Summary for C4 Therapeutics Inc (CCCC) - $2.54 as of 4/10/2026 8:37:27 PM EST
Total Score
11 out of 30
Safety Score
35 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CCCC
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CCCC
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CCCC
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CCCC
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CCCC (35 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 6 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for CCCC
Financial Details for CCCC
Company Overview |
|
|---|---|
| Ticker | CCCC |
| Company Name | C4 Therapeutics Inc |
| Country | USA |
| Description | C4 Therapeutics, Inc., a biopharmaceutical company, develops new therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company is headquartered in Watertown, Massachusetts. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 12/31/2025 |
| Next Earnings Date | 5/6/2026 |
Stock Price History |
|
| Last Day Price | 2.54 |
| Price 4 Years Ago | 5.90 |
| Last Day Price Updated | 4/10/2026 8:37:27 PM EST |
| Last Day Volume | 3,909,493 |
| Average Daily Volume | 3,201,868 |
| 52-Week High | 3.82 |
| 52-Week Low | 1.09 |
| Last Price to 52 Week Low | 133.03% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 43.01 |
| Sector PE | 38.13 |
| 5-Year Average PE | -1.63 |
| Free Cash Flow Ratio | 3.34 |
| Industry Free Cash Flow Ratio | 14.85 |
| Sector Free Cash Flow Ratio | 22.07 |
| Current Ratio Most Recent Quarter | 7.81 |
| Total Cash Per Share | 0.76 |
| Book Value Per Share Most Recent Quarter | 2.65 |
| Price to Book Ratio | 1.07 |
| Industry Price to Book Ratio | 105.79 |
| Sector Price to Book Ratio | 23.58 |
| Price to Sales Ratio Twelve Trailing Months | 7.68 |
| Industry Price to Sales Ratio Twelve Trailing Months | 16.68 |
| Sector Price to Sales Ratio Twelve Trailing Months | 5.73 |
| Analyst Buy Ratings | 7 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 97,578,000 |
| Market Capitalization | 247,848,120 |
| Institutional Ownership | 78.30% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 0.31% |
| Reported EPS 12 Trailing Months | -1.27 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | -1.36 |
| Net Income Twelve Trailing Months | -104,994,000 |
| Net Income Past Year | -104,994,000 |
| Net Income Prior Year | -105,316,000 |
| Quarterly Revenue Growth YOY | 112.80% |
| 5-Year Revenue Growth | 1.61% |
| Operating Margin Twelve Trailing Months | -210.10% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 74,603,000 |
| Total Cash Past Year | 74,603,000 |
| Total Cash Prior Year | 55,499,000 |
| Net Cash Position Most Recent Quarter | 64,268,000 |
| Net Cash Position Past Year | 63,121,000 |
| Long Term Debt Past Year | 11,482,000 |
| Long Term Debt Prior Year | 11,482,000 |
| Total Debt Most Recent Quarter | 10,335,000 |
| Equity to Debt Ratio Past Year | 0.96 |
| Equity to Debt Ratio Most Recent Quarter | 0.96 |
| Total Stockholder Equity Past Year | 256,587,000 |
| Total Stockholder Equity Prior Year | 215,986,000 |
| Total Stockholder Equity Most Recent Quarter | 256,587,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -99,301,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.02 |
| Free Cash Flow Past Year | -99,301,000 |
| Free Cash Flow Prior Year | -65,337,000 |
Options |
|
| Put/Call Ratio | 1.09 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.06 |
| MACD Signal | 0.05 |
| 20-Day Bollinger Lower Band | 1.64 |
| 20-Day Bollinger Middle Band | 2.37 |
| 20-Day Bollinger Upper Band | 3.11 |
| Beta | 2.86 |
| RSI | 55.71 |
| 50-Day SMA | 2.22 |
| 150-Day SMA | 3.74 |
| 200-Day SMA | 4.63 |
System |
|
| Modified | 4/10/2026 8:04:29 PM EST |